Physician profile
Rajendra Bobba
NPI 1023006749
$1,348.65
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $61.69 · 2021: $295 · 2022: $936 · 2023: $56.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $399.74 | 2021-2022 | |
| Abbvie INC. | $260.84 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.30 | 2020-2022 | |
| Qol Medical, LLC | $180.26 | 2021-2022 | |
| Pentax of America, INC. | $56.07 | 2023 | Pentax Medical, Video Colonoscope |
| Genzyme Corporation | $49.25 | 2022 | |
| Ferring Pharmaceuticals INC. | $45.73 | 2021 | |
| Evoke Pharma, INC. | $25.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.01 | 2022 | |
| Celgene Corporation | $21.64 | 2022 | |
| Redhill Biopharma INC. | $20.22 | 2021 | |
| Janssen Biotech, INC. | $16.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajendra Bobba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.